Astellas/Seagen, Merck drug combo shows promise in bladder cancer subtype in trial

Jul. 26, 2022 5:14 AM ETSeagen Inc. (SGEN), ALPMY, MRK, ALPMFBy: Ravikash, SA News Editor3 Comments

Human Urinary System Kidneys with Bladder Anatomy


Astellas Pharma (OTCPK:ALPMY) (OTCPK:ALPMF) and Seagen (NASDAQ:SGEN) said Cohort K of a phase 1b/2 trial of their drug Padcev in combination with Merck's (NYSE:MRK) Keytruda showed response in certain patients with a type of bladder cancer.

In the group K

Recommended For You

Comments (3)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.